Ohr Pharmaceutical Inc (OHRP) 8.96 $OHRP
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Technical Analysis on Health Care Sector Equities -- Research on Ohr Pharma, Synta Pharma, Agenus, and PDL BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
The trading session on Tuesday, July 08, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,906.62, down 0.69% and the NASDAQ Composite closed at 4,391.46, down 1.35%. The S&P 500 finished the day 0.70% lower at 1,963.71. The losses were broad based as nine out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day at 709.36, down 0.92%, while the index has advanced 2.11% in the previous one month. Investor-Edge has initiated coverage on the following equities: Ohr Pharmaceutical Inc. (NASDAQ: OHRP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Agenus Inc. (NASDAQ: AGEN) and PDL BioPharma Inc. (NASDAQ: PDLI). Free technical research on OHRP, SNTA, AGEN and PDLI can be downloaded upon signing up at:
Ohr Pharmaceutical Added to the Russell Indexes
GlobeNewswire - Mon Jun 30, 8:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global, Russell 3000, and the Russell Microcap Indexes when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.
Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today
at The Street - Thu Jun 26, 3:21PM CDT
Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31
Marketwire - Thu Jun 26, 8:02AM CDT
Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR"
and raised its twelve month price target from $14 to $31. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, currently in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD), a chronic eye disease that causes vision loss in the center of your field of vision. Therapies for Wet-AMD such as ranibizumab (Lucentis(R)) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea(R)) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $6B of revenues in 2013. OHR's Wet-AMD clinical candidate Squalamine eye drops showed gains in visual acuity according to the interim data presented Tuesday this week. The current forms of approved treatment, Lucentis(R) and Eylea(R), require an injection into the back of the eye. Also in clinical development, Opthotech's Fovista(R), requires an injection into the back of the eye post an initial Lucentis(R) injection and is being developed to increase visual acuity. Squalamine Eye Drops would seem to present a significant advantage relative to the aforementioned therapy (Fovista(R)) considering Squalamine Eye Drops delivery method which is self-administered eye drops. Squalamine Eye Drops may have the potential to create a monumental shift in the way patients are treated for Wet-AMD if approved. The positive visual acuity results also provide a possible trajectory for a Phase 3 trial design." Mr. Silver concludes, "OHR completed an equity financing of $18M in April 2014, which according to the Company, gives them a cash runway well into 2016."
Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
at The Street - Tue Jun 24, 11:07AM CDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 8:18AM CDT
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise by almost 17% on the day.
Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD
GlobeNewswire - Tue Jun 24, 6:00AM CDT
-- Patients treated with Squalamine eye drops plus Lucentis PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN
Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD
GlobeNewswire - Mon Jun 23, 3:30PM CDT
Webcast to be Held on Tuesday, June 24 at 8:30am Eastern
5 Stocks Setting Up to Break Out
at The Street - Mon Jun 23, 8:37AM CDT
These stocks look poised to break out and trade higher from current level.s
Onconova Therapeutics (ONTX) in Focus: Stock Up 14.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:46AM CDT
Onconova Therapeutics (ONTX) was a big mover last session, with shares rising just over 14% on the day.
Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:25AM CDT
Recro Pharma (REPH) was a big mover last session, with shares rising over 6% on the day.
Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
Marketwire - Thu Jun 05, 1:48AM CDT
Vista Partners ("Vista" published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Technical Analysis on Health Care Sector Equities -- Research on Ohr Pharma, Synta Pharma, Agenus, and PDL BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
The trading session on Tuesday, July 08, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,906.62, down 0.69% and the NASDAQ Composite closed at 4,391.46, down 1.35%. The S&P 500 finished the day 0.70% lower at 1,963.71. The losses were broad based as nine out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day at 709.36, down 0.92%, while the index has advanced 2.11% in the previous one month. Investor-Edge has initiated coverage on the following equities: Ohr Pharmaceutical Inc. (NASDAQ: OHRP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Agenus Inc. (NASDAQ: AGEN) and PDL BioPharma Inc. (NASDAQ: PDLI). Free technical research on OHRP, SNTA, AGEN and PDLI can be downloaded upon signing up at:
Ohr Pharmaceutical Added to the Russell Indexes
GlobeNewswire - Mon Jun 30, 8:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global, Russell 3000, and the Russell Microcap Indexes when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.
Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today
at The Street - Thu Jun 26, 3:21PM CDT
Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31
Marketwire - Thu Jun 26, 8:02AM CDT
Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR"
and raised its twelve month price target from $14 to $31. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, currently in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD), a chronic eye disease that causes vision loss in the center of your field of vision. Therapies for Wet-AMD such as ranibizumab (Lucentis(R)) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea(R)) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $6B of revenues in 2013. OHR's Wet-AMD clinical candidate Squalamine eye drops showed gains in visual acuity according to the interim data presented Tuesday this week. The current forms of approved treatment, Lucentis(R) and Eylea(R), require an injection into the back of the eye. Also in clinical development, Opthotech's Fovista(R), requires an injection into the back of the eye post an initial Lucentis(R) injection and is being developed to increase visual acuity. Squalamine Eye Drops would seem to present a significant advantage relative to the aforementioned therapy (Fovista(R)) considering Squalamine Eye Drops delivery method which is self-administered eye drops. Squalamine Eye Drops may have the potential to create a monumental shift in the way patients are treated for Wet-AMD if approved. The positive visual acuity results also provide a possible trajectory for a Phase 3 trial design." Mr. Silver concludes, "OHR completed an equity financing of $18M in April 2014, which according to the Company, gives them a cash runway well into 2016." Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
at The Street - Tue Jun 24, 11:07AM CDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 8:18AM CDT
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise by almost 17% on the day.
Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD
GlobeNewswire - Tue Jun 24, 6:00AM CDT
-- Patients treated with Squalamine eye drops plus Lucentis PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN
Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD
GlobeNewswire - Mon Jun 23, 3:30PM CDT
Webcast to be Held on Tuesday, June 24 at 8:30am Eastern
5 Stocks Setting Up to Break Out
at The Street - Mon Jun 23, 8:37AM CDT
These stocks look poised to break out and trade higher from current level.s
Onconova Therapeutics (ONTX) in Focus: Stock Up 14.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:46AM CDT
Onconova Therapeutics (ONTX) was a big mover last session, with shares rising just over 14% on the day.
Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:25AM CDT
Recro Pharma (REPH) was a big mover last session, with shares rising over 6% on the day.
Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
Marketwire - Thu Jun 05, 1:48AM CDT
Vista Partners ("Vista"
published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. 
